Hims & Hers Health, Inc. (NYSE:HIMS) Position Cut by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. lessened its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 33.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 283,650 shares of the company's stock after selling 145,650 shares during the quarter. Hillsdale Investment Management Inc. owned about 0.13% of Hims & Hers Health worth $2,524,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in HIMS. Graham Capital Management L.P. raised its holdings in Hims & Hers Health by 39.4% in the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company's stock valued at $2,141,000 after acquiring an additional 96,277 shares in the last quarter. Forerunner Ventures Management LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at approximately $86,836,000. Swiss National Bank raised its holdings in Hims & Hers Health by 9.2% in the third quarter. Swiss National Bank now owns 309,200 shares of the company's stock valued at $1,945,000 after acquiring an additional 26,100 shares in the last quarter. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 3.1% in the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company's stock valued at $88,857,000 after acquiring an additional 428,671 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Hims & Hers Health by 11.5% in the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company's stock valued at $3,551,000 after acquiring an additional 58,288 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity at Hims & Hers Health

In related news, insider Irene Becklund sold 2,747 shares of Hims & Hers Health stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $12.08, for a total value of $33,183.76. Following the transaction, the insider now directly owns 5,494 shares in the company, valued at approximately $66,367.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 63,621 shares of the firm's stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $15.17, for a total value of $965,130.57. Following the completion of the sale, the insider now owns 154,345 shares of the company's stock, valued at $2,341,413.65. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Irene Becklund sold 2,747 shares of the firm's stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $12.08, for a total value of $33,183.76. Following the completion of the sale, the insider now directly owns 5,494 shares of the company's stock, valued at approximately $66,367.52. The disclosure for this sale can be found here. Insiders have sold a total of 589,638 shares of company stock worth $8,356,389 in the last three months. Insiders own 17.71% of the company's stock.

Hims & Hers Health Price Performance

Shares of HIMS traded up $4.04 during mid-day trading on Monday, reaching $18.61. 70,484,022 shares of the company's stock were exchanged, compared to its average volume of 5,951,859. The business's fifty day simple moving average is $14.00 and its 200-day simple moving average is $10.89. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $20.11. The stock has a market capitalization of $4.00 billion, a PE ratio of -1,861.00 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The firm had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. During the same period last year, the firm posted ($0.05) EPS. Hims & Hers Health's quarterly revenue was up 45.8% on a year-over-year basis. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

HIMS has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $14.00 to $16.00 and gave the company a "hold" rating in a report on Tuesday, May 7th. SVB Leerink initiated coverage on shares of Hims & Hers Health in a research note on Monday, February 26th. They issued a "market perform" rating and a $10.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They issued a "buy" rating and a $20.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They issued a "buy" rating and a $20.00 price target on the stock. Finally, Imperial Capital upgraded shares of Hims & Hers Health from an "in-line" rating to an "outperform" rating and set a $16.00 price target on the stock in a research note on Wednesday, February 28th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $15.08.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.